维那卡兰；794466-70-9

Vernakalant

询价 25kg/桶起订

陕西更新日期：2026-09-18

陕西西化化学工业有限公司

VIP1年

联系人：王经理

手机：18161915376 拨打

邮箱：1096@dideu.com

产品详情:

中文名称：: 维那卡兰

英文名称：: Vernakalant

CAS号：: 794466-70-9

纯度规格：: 98%

产品类别：: 中间体

级别：: 医药级

分子式：: C20H31NO4

业务负责人：: 负责人：汪经理：17392713612微信同号，QQ：1655706449

中文名	维那卡兰
英文名	(3R)-1-[(1R,2R)-2-[2-(3,4-dimethoxyphenyl)ethoxy]cyclohexyl]pyrrolidin-3-ol
英文别名	更多

描述	Vernakalant(RSD-1235)是混合型离子通道阻断剂,在2到5 mg/kg剂量下,能终止急性心房颤动。
相关类别	信号通路 >> 跨膜转运 >> 钾通道研究领域 >> 心血管疾病
参考文献	[1]. Dorian, Paul MD et al. The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans. Journal of Cardiovascular Pharmacology:July 2007 - Volume 50 -Issue 1 - pp 35-40. [2]. Jodene Eldstrom et al. The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels. Molecular Pharmacology December 2007 vol. 72 no. 6 1522-1534 [3]. Vernakalant. Too dangerous in atrial fibrillation.Prescrire Int. 2012 May;21(127):119-22. [4]. Blomstr?m-Lundqvist C, Blomstr?m P.Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.Expert Opin Drug Saf. 2012 Jul;11(4):671-9. Epub 2012 May 26. [5]. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R, Mwamburi M.Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.Cardiovasc Drugs Ther. 2012 Apr;

描述

Vernakalant(RSD-1235)是混合型离子通道阻断剂,在2到5 mg/kg剂量下,能终止急性心房颤动。

相关类别

信号通路 >> 跨膜转运 >> 钾通道

研究领域 >> 心血管疾病

参考文献

[1]. Dorian, Paul MD et al. The Effect of Vernakalant (RSD1235), an Investigational Antiarrhythmic Agent, on Atrial Electrophysiology in Humans. Journal of Cardiovascular Pharmacology:July 2007 - Volume 50 -Issue 1 - pp 35-40.

[2]. Jodene Eldstrom et al. The Molecular Basis of High-Affinity Binding of the Antiarrhythmic Compound Vernakalant (RSD1235) to Kv1.5 Channels. Molecular Pharmacology December 2007 vol. 72 no. 6 1522-1534

[3]. Vernakalant. Too dangerous in atrial fibrillation.Prescrire Int. 2012 May;21(127):119-22.

[4]. Blomstr?m-Lundqvist C, Blomstr?m P.Safety and efficacy of pharmacological cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity.Expert Opin Drug Saf. 2012 Jul;11(4):671-9. Epub 2012 May 26.

[5]. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R, Mwamburi M.Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation.Cardiovasc Drugs Ther. 2012 Apr;

密度	1.1±0.1 g/cm3
沸点	479.0±45.0 °C at 760 mmHg
分子式	C20H31NO4
分子量	349.464
闪点	243.5±28.7 °C
精确质量	349.225311
PSA	51.16000
LogP	2.40
InChIKey	VBHQKCBVWWUUKN-KZNAEPCWSA-N
SMILES	COc1ccc(CCOC2CCCCC2N2CCC(O)C2)cc1OC
蒸汽压	0.0±1.3 mmHg at 25°C
折射率	1.557